Free tool
FDA Approval Tracker
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations
Matching approvals
1,601
2015 to 2026
Breakthrough
186
Accelerated
125
Priority review
510
Orphan
469
By year
NDAs and BLAs matching the filters.
- NDA
- BLA
View as table
| Year | NDA | BLA |
|---|---|---|
| 2015 | 101 | 19 |
| 2016 | 87 | 15 |
| 2017 | 124 | 24 |
| 2018 | 131 | 24 |
| 2019 | 110 | 23 |
| 2020 | 110 | 22 |
| 2021 | 103 | 21 |
| 2022 | 106 | 25 |
| 2023 | 107 | 29 |
| 2024 | 92 | 44 |
| 2025 | 112 | 52 |
| 2026 | 89 | 31 |
1,601 approvals
Newest first. Hover a badge for what it means.
- Klygefa (Gefurulimab) · Alexion PharmNov 13, 2026Original approval · BLA 761488NovelOrphan
To treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis
- Pebrilzo (Pertuzumab) · Biocon Biologics INCNov 12, 2026Original approval · BLA 761501Approval letter
- Pimjetmi (Pimicotinib) · Emd SeronoNov 10, 2026
To treat adults with symptomatic tenosynovial giant cell tumors in whom surgical resection may cause worsening functional limitation or severe morbidity
- Oxderys (Doxorubicin Hydrochloride) · Avyxa HoldingsNov 9, 2026Original approval · NDA 221093Approval letter
- Multibic (Multibic) · Fresenius Medical Care Renal Therapies Group LLCNov 9, 2026Original approval · NDA 219457Approval letter
- Sunharbo (Asundexian) · Bayer HealthcareNov 9, 2026
To reduce the risk of stroke in adults following a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack
- Axycis (Cisplatin) · Avyxa HoldingsOct 29, 2026Original approval · NDA 220748Approval letter
- Lucamzi (Ranibizumab-Blrz) · Xbrane Biopharma AbOct 27, 2026Original approval · BLA 761187Approval letter
- Enzeevu (Aflibercept-Abzv) · Sandoz INCOct 22, 2026Original approval · BLA 761382Approval letter
- Ahzantive (Aflibercept-Mrbb) · Formycon AGOct 22, 2026Original approval · BLA 761378Approval letter
- Pavblu (Aflibercept-Ayyh) · Amgen INCOct 22, 2026Original approval · BLA 761298Approval letter
- Hibsago (Bepirovirsen Sodium) · GlaxosmithklineOct 20, 2026
To treat chronic hepatitis B virus infection in certain adults without cirrhosis, in combination with existing antiviral therapy
- Calrezdy (Calcium Chloride) · Fresenius Medcl CareOct 19, 2026Original approval · NDA 219456Approval letter
- Cienby (Trisodium Citrate) · Fresenius Medcl CareOct 19, 2026Original approval · NDA 219455Approval letter
- Brytly (Apraclonidine Hydrochloride) · Alcon Labs INCOct 16, 2026Original approval · NDA 220341Approval letter
- Yulzety (Rivaroxaban) · Rosemont PharmsOct 16, 2026Original approval · NDA 221033Approval letter
- Evoxac (Cevimeline Hydrochloride) · CosetteOct 15, 2026Original approval · NDA 221183Approval letter
- Isovue Readi (Iopamidol) · BraccoOct 9, 2026Original approval · NDA 220583Approval letter
- Hovilpri (Pritelivir Mesylate) · Aicuris Anti-InfectOct 9, 2026
To treat adults with weakened immune systems who have mucocutaneous lesions caused by herpes simplex virus infection and have not responded to other therapies
- Weltruza (Olanzapine) · TevaOct 8, 2026Original approval · NDA 219007Approval letter
- Breztri Aerosphere (Budesonide, Formoterol Fumarate, Glycopyrrolate) · Astrazeneca AbOct 8, 2026Original approval · NDA 220290Approval letter
- Trabectedin (Trabectedin) · EverOct 1, 2026Original approval · NDA 219617Approval letter
- Emcitate (Tiratricol) · Rare ThyroidSep 28, 2026
To treat peripheral thyrotoxicosis in patients with MCT8 deficiency
- Juvmo (Tavapadon) · AbbvieSep 25, 2026
To treat Parkinson's disease in adults
- Atebrioz (Zilurgisertib Fumarate) · MirumSep 25, 2026
To reduce the volume of total new heterotopic ossification in adults and pediatric patients 12 years and older with fibrodysplasia ossificans progressiva
- Lamlique (Lamotrigine Hemifumarate) · AzuritySep 25, 2026Original approval · NDA 221109Approval letter
- Zueino (Diclofenac Sodium) · AdventapharmaSep 25, 2026Original approval · NDA 218379Approval letter
- Degevma (Denosumab-Adet) · Teva Pharmaceuticals, Inc.Sep 25, 2026Original approval · BLA 761481Approval letter
- Lyrfigtu (Lirafugratinib Hydrochloride) · ElevarSep 23, 2026
To adults with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring a fibroblast growth factor receptor 2 gene fusion or other rearrangement
- Onswik (Insulin Efsitora Alfa-Gobe) · Eli Lilly and COSep 23, 2026
To improve glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise
- Carbon Dioxide, Usp (Carbon Dioxide, Usp) · Agl Welding Supply CO INC Dba Agl Gas TechnologiesSep 22, 2026Original approval · NDA 222000Approval letter
- Garzulys (Insulin Aspart-Fsan) · Emerge Bioscience Pte. Ltd.Sep 15, 2026Original approval · BLA 761497Approval letter
- Bexlutry (Lutetium Lu-177 Dotatate) · CuriumSep 14, 2026Original approval · NDA 218525Approval letter
- Isembyld (Apitegromab-Mstn) · Scholar Rock INCSep 11, 2026
To treat spinal muscular atrophy in adults and pediatric patients 2 years of age and older who are currently receiving an SMN2-targeted treatment
- Pixclara (Floretyrosine F-18) · TelixSep 11, 2026
To use with positron emission tomography to differentiate recurrent or progressive glioma from treatment-related change in conjunction with other diagnostic evaluations
- Etcamah (Camizestrant) · AstrazenecaSep 4, 2026
To treat hormone receptor-positive, human epidermal growth factor receptor 2-negative, locally advanced or metastatic breast cancer upon detection of ESR1 mutation during aromatase inhibitor and CDK4/6 inhibitor therapy
- Zanvastro (Zilganersen Sodium) · Ionis Pharms INCSep 3, 2026
To treat Alexander disease in pediatric and adult patients
- Omcazio (Cabozantinib Laurylsulfate) · Handa OncolSep 3, 2026Original approval · NDA 220613Approval letter
- Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
To treat erythrocytosis in adults with polycythemia vera
- Bixlenvo (Bictegravir Sodium, Lenacapavir Sodium) · Gilead Sciences INCAug 27, 2026
- Lisraya (Brepocitinib Tosylate) · Priovant TherapAug 27, 2026
To treat dermatomyositis in adults
- Bixlenvo Sunlenca Starter Pack (Copackaged) (Bictegravir Sodium, Lenacapavir Sodium, Lenacapavir Sodium) · Gilead Sciences INCAug 27, 2026Original approval · NDA 221443Approval letter
- Rasonque (Daraxonrasib) · Revolution MedicinesAug 26, 2026
To treat metastatic pancreatic cancer
- Vobrig (Leuprolide Acetate) · Sun PharmAug 26, 2026Original approval · NDA 213225Approval letter
- Pasatru (Garetosmab-Grts) · Regeneron Pharmaceuticals, INCAug 19, 2026
To reduce new heterotopic ossification and clinician-assessed disease flare-ups in adults with fibrodysplasia ossificans progressiva
- Sodium Bicarbonate (Sodium Bicarbonate) · Baxter Hlthcare CorpAug 14, 2026Original approval · NDA 218524Approval letter
- Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent
- Tauklarify (Florquinitau F-18) · Cerveau LantheusAug 13, 2026
To be used for positron emission tomography of the brain in adults with cognitive impairment who are being evaluated for Alzheimer disease to identify patients with tau neurofibrillary tangle pathology
- Nitrous Oxide, Usp (Nitrous Oxide) · Linde Gas EquipAug 9, 2026Original approval · NDA 221892Approval letter
- Orzeyful (Oveporexton) · Takeda Pharms USAAug 5, 2026
To treat narcolepsy type 1
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.